Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
Recent advances in radionuclide therapy offer a new approach for the management of metastatic bone pain. This paper reports the results of dosage escalation studies with 186Re-HEDP as a bone-seeking radiopharmaceutical in patients with bone metastases originating from breast or prostate cancer with regard to toxicity, pharmacokinetics and bone marrow dosimetry and the palliating effect on bone pain. Thrombocytopenia proved to be the dose limiting factor and 186Re-HEDP showed a considerable efficacy in end-stage patients with metastatic bone pain.
De Klerk
J M
JM
Department of Nuclear Medicine, University Hospital Utrecht, The Netherlands.
Zonnenberg
B A
BA
Blijham
G H
GH
Van Het Schip
A D
AD
Hoekstra
A
A
Han
S H
SH
Quirijnen
J M
JM
Van Dijk
A
A
Van Rijk
P P
PP
D001859:Bone Neoplasms / Q000503:physiopathology / Q000532:radiotherapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000503:physiopathology / Q000532:radiotherapy*; D012968:Etidronic Acid / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009942:Organometallic Compounds; D010148:Intractable Pain; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000503:physiopathology / Q000532:radiotherapy*; D019275:Radiopharmaceuticals; D012211:Rhenium / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000209:etiology
D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C101598:rhenium-186 HEDP; D012211:Rhenium; D017430:Prostate-Specific Antigen; D012968:Etidronic Acid